Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

New Strong Buy Stocks for February 23rd

AMN, AN, BAK, CBOE, and TPH have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2022.

Should Value Investors Pick AMN Healthcare Services (AMN)?

Let's see if AMN Healthcare Services (AMN) stock is a good choice for value-oriented investors right now from multiple angles.

Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod

Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.

NextGen (NXGN)-Verato Tie Up to Improve Patient Insights

NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.

AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?

Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.

AMN vs. GDRX: Which Stock Should Value Investors Buy Now?

AMN vs. GDRX: Which Stock Is the Better Value Option?

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.

AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.

OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?

OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.

Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe

According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.

Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.

LabCorp (LH) Expands Clinical Laboratory Services With New Pact

LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.

What's in Store for West Pharmaceutical's (WST) Q4 Earnings?

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.

Baxter (BAX) to Report Q4 Earnings: What's in the Offing?

Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.

Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?

Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.

Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore

Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.

Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass

Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.